Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 89 articles:
HTML format



Single Articles


    March 2021
  1. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  2. CHUAYPEN N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis. 2021 Feb 17. pii: 6141513. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  3. KHERA T, Du Y, Todt D, Deterding K, et al
    Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.
    J Infect Dis. 2021 Jan 31. pii: 6124746. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  4. JEYARAJAN AJ, Chung RT
    Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  5. BAJIS S, Applegate TL, Grebely J, Matthews GV, et al
    Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  6. CHAPPELL CA, Jonas MM
    Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
    J Infect Dis. 2020;222.
    PubMed    


  7. THOMAS DL
    30 Years on the Road to Hepatitis C Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  8. NAGGIE S, Wyles D
    Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  9. FALADE-NWULIA O, Sulkowski MS
    Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  10. TROOSKIN SB, Dore G, Kostman J
    We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  11. ROCKSTROH JK, Boesecke C
    Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  12. KAPPUS MR, Wolfe CR, Muir AJ
    Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  13. HALEY DF, Edmonds A, Ramirez C, French AL, et al
    Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV.
    J Infect Dis. 2020 Nov 3. pii: 5952700. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  14. VERGARA C, Valencia A, Thio CL, Goedert JJ, et al
    A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
    J Infect Dis. 2020 Oct 29. pii: 5943036. doi: 10.1093.
    PubMed     Abstract available


  15. MESALAM AA
    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    PubMed    


    September 2020
  16. JORDAN AE, Cleland CM, Wyka K, Schackman BR, et al
    Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  17. LEE AB, Karumberia S, Gilmore A, Williams E, et al
    Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  18. SHERBUK JE, Knick TK, Canan C, Ross P, et al
    Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  19. JORDAN AE, Cleland CM, Schackman BR, Wyka K, et al
    Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  20. ASSOUMOU SA, Paniagua SM, Linas BP, Wang J, et al
    Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  21. WESNER CA, Zhang W, Melstad S, Ruen E, et al
    Assessing County-Level Vulnerability for Opioid Overdose and Rapid Spread of Human Immunodeficiency Virus and Hepatitis C Infection in South Dakota.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  22. WINETSKY D, Burack D, Antoniou P, Garcia B, et al
    Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  23. SPRINGER SA, Barocas JA, Wurcel A, Nijhawan A, et al
    Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  24. ROWAN SE, Kamis KF, Beum R, Bryan K, et al
    Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


    August 2020
  25. CAPPY P, Lucas Q, Kankarafou N, Sureau C, et al
    No Evidence of HCV-Assisted HDV Propagation in a Large Cohort of Hepatitis C Positive Blood Donors.
    J Infect Dis. 2020 Aug 17. pii: 5893459. doi: 10.1093.
    PubMed     Abstract available


  26. WIJAYA RS, Read SA, Selvamani SP, Schibeci S, et al
    Hepatitis C virus eradication with interferon free, DAA-based therapy results in KLRG1+, hepatitis C virus-specific memory natural killer cells.
    J Infect Dis. 2020 Aug 10. pii: 5890638. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  27. CATLETT B, Bajis S, Starr M, Dore GJ, et al
    Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples.
    J Infect Dis. 2020 Jul 25. pii: 5876378. doi: 10.1093.
    PubMed     Abstract available


  28. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study.
    J Infect Dis. 2020 Jul 2. pii: 5866494. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  29. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals.
    J Infect Dis. 2020 Jun 25. pii: 5862583. doi: 10.1093.
    PubMed     Abstract available


  30. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication.
    J Infect Dis. 2020 Jun 9. pii: 5854965. doi: 10.1093.
    PubMed     Abstract available


  31. NAGGIE S, Lusk S, Thompson JW, Mock M, et al
    Metabolomic signature as a predictor of liver disease events in patients with HIV/HCV co-infection.
    J Infect Dis. 2020 Jun 5. pii: 5851922. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  32. ANTHONY DD, Sulkowski MS, Smeaton LM, Damjanovska S, et al
    HCV DAA Therapy in Persons with HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation.
    J Infect Dis. 2020 May 15. pii: 5836999. doi: 10.1093.
    PubMed     Abstract available


  33. DASGUPTA S, Imamura M, Gorstein E, Nakahara T, et al
    Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration.
    J Infect Dis. 2020 May 4. pii: 5828592. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  34. BALAGOPAL A, Smeaton LM, Quinn J, Venuto CS, et al
    Intrahepatic Viral Kinetics during Direct-Acting Antivirals for Hepatitis C in HIV Co-infection:The ACTG A5335S Substudy.
    J Infect Dis. 2020 Mar 23. pii: 5810960. doi: 10.1093.
    PubMed     Abstract available


  35. SUN B, Abadjian L, Monto A, Freasier H, et al
    HCV cure in HIV coinfection dampens inflammation and improves cognition through multiple mechanisms.
    J Infect Dis. 2020 Mar 11. pii: 5802775. doi: 10.1093.
    PubMed     Abstract available


  36. AKIYAMA MJ, Lipsey D, Ganova-Raeva L, Punkova L, et al
    A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
    J Infect Dis. 2020 Mar 9. pii: 5801905. doi: 10.1093.
    PubMed     Abstract available


    February 2020
  37. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Erratum to: Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C.
    J Infect Dis. 2020 Feb 15. pii: 5736576. doi: 10.1093.
    PubMed    


    January 2020
  38. LINAS BP
    Time for a New Approach to Guidance for HIV and HCV Testing Among Persons Who Inject Drugs.
    J Infect Dis. 2020 Jan 30. pii: 5718241. doi: 10.1093.
    PubMed    


  39. BULL-OTTERSON L, Huang YA, Zhu W, King H, et al
    HIV and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017.
    J Infect Dis. 2020 Jan 30. pii: 5718242. doi: 10.1093.
    PubMed     Abstract available


  40. GREBELY J, Catlett B, Jayasinghe I, Valerio H, et al
    Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a more rapid time to diagnosis.
    J Infect Dis. 2020 Jan 29. pii: 5717213. doi: 10.1093.
    PubMed     Abstract available


  41. CLIPMAN SJ, Duggal P, Srikrishnan AK, Saravanan S, et al
    Prevalence and phylogenetic characterization of hepatitis C among men who have sex with men in India: limited evidence for sexual transmission.
    J Infect Dis. 2020 Jan 9. pii: 5699640. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  42. KOVACS AAZ, Kono N, Wang CH, Wang D, et al
    Association of HLA Genotype With T-Cell Activation in Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus-Coinfected Women.
    J Infect Dis. 2019 Nov 10. pii: 5618844. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  43. ZOU B, Yeo YH, Le MH, Henry L, et al
    Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.
    J Infect Dis. 2019 Sep 27. pii: 5575100. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  44. KOSLOSKI MP, Oberoi R, Wang S, Viani RM, et al
    Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.
    J Infect Dis. 2019 Aug 29. pii: 5556482. doi: 10.1093.
    PubMed     Abstract available


  45. EMMANUEL B, El-Kamary SS, Magder LS, Stafford KA, et al
    Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-DeltaG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.
    J Infect Dis. 2019 Aug 26. pii: 5554606. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  46. MARTIN NK, Jansen K, An der Heiden M, Boesecke C, et al
    Can HCV be eliminated among HIV-positive men who have sex with men in Berlin? A modeling analysis.
    J Infect Dis. 2019 Jul 12. pii: 5532024. doi: 10.1093.
    PubMed     Abstract available


    June 2019
  47. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis C.
    J Infect Dis. 2019 Jun 4. pii: 5511345. doi: 10.1093.
    PubMed     Abstract available


  48. HAN JW, Sung PS, Kim KH, Hong SH, et al
    Dynamic Changes in Ex Vivo T-Cell Function after Viral Clearance in Chronic HCV Infection.
    J Infect Dis. 2019 Jun 1. pii: 5510067. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  49. YAN Y, Wang X, Lou P, Hu Z, et al
    A nanoparticle-based HCV vaccine with enhanced potency.
    J Infect Dis. 2019 May 10. pii: 5487910. doi: 10.1093.
    PubMed     Abstract available


  50. LAIDLAW SM, Dustin LB
    An HCV vaccine on the fly.
    J Infect Dis. 2019 May 10. pii: 5487908. doi: 10.1093.
    PubMed    


    April 2019
  51. DOUGLAS MW, Tay ES, Eden JS, George J, et al
    Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir.
    J Infect Dis. 2019 Apr 8. pii: 5431216. doi: 10.1093.
    PubMed    


  52. HUANG CF, Hung CH, Cheng PN, Bair MJ, et al
    An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated subst
    J Infect Dis. 2019 Apr 8. pii: 5430846. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  53. ABARA WE, Trujillo L, Broz D, Finlayson T, et al
    Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015.
    J Infect Dis. 2019 Mar 27. pii: 5420467. doi: 10.1093.
    PubMed     Abstract available


  54. KUSEJKO K, Bachmann N, Chaudron SE, Nguyen H, et al
    A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, non-communicable and opportunistic diseases.
    J Infect Dis. 2019 Mar 4. pii: 5369724. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  55. SALAZAR-VIZCAYA L, Kouyos RD, Metzner KJ, Caraballo Cortes K, et al
    Changing trends in international versus domestic HCV transmission in HIV-positive MSM: A perspective for the DAA scale-up era.
    J Infect Dis. 2019 Feb 13. pii: 5318573. doi: 10.1093.
    PubMed     Abstract available


  56. LEUNG J, Peacock A, Colledge S, Grebely J, et al
    A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?
    J Infect Dis. 2019 Feb 6. pii: 5307802. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  57. RAGHWANI J, Wu CH, Ho CKY, De Jong M, et al
    High resolution evolutionary analysis of within-host hepatitis C virus infection.
    J Infect Dis. 2019 Jan 2. pii: 5269822. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  58. PIROZYAN MR, Nguyen N, Cameron B, Luciani F, et al
    Chemokine-regulated recruitment of antigen-specific T cell sub-populations to the liver in acute and chronic hepatitis C infection.
    J Infect Dis. 2018 Nov 29. pii: 5213654. doi: 10.1093.
    PubMed     Abstract available


  59. PRICE JC, McKinney JE, Crouch PC, Dillon SM, et al
    Sexually Acquired Hepatitis C Infection in HIV-uninfected Men Who Have Sex with Men Using Pre-exposure Prophylaxis Against HIV.
    J Infect Dis. 2018 Nov 20. pii: 5193510. doi: 10.1093.
    PubMed     Abstract available


  60. YEH ML, Huang CI, Huang CF, Hsieh MH, et al
    Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients.
    J Infect Dis. 2018 Nov 19. pii: 5191105. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  61. LAROUCHE A, Milton McSween KA, Calderon V, Fauteux-Daniel S, et al
    Quasispecies Diversity Is a Major Risk Factor for Vertical Hepatitis C Virus Transmission.
    J Infect Dis. 2018 Oct 25. pii: 5144832. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  62. THOENS C, Heinold A, Lindemann M, Horn PA, et al
    A single nucleotide polymorphism upstream of the HLA-C locus is associated with an anti-HCV seronegative state in a high-risk exposed cohort.
    J Infect Dis. 2018 Aug 9. pii: 5068404. doi: 10.1093.
    PubMed     Abstract available


  63. VELAZQUEZ-MOCTEZUMA R, Galli A, Law M, Bukh J, et al
    Hepatitis C virus escape studies for human monoclonal antibody AR4A reveal isolate-specific resistance and a high barrier to resistance.
    J Infect Dis. 2018 Aug 9. pii: 5068268. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  64. LOPEZ-CORTES LF, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo OJ, et al
    Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    J Infect Dis. 2018 Jul 6. pii: 5050122. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  65. BORGIA SM, Hedskog C, Parhy B, Hyland RH, et al
    Identification of a Novel Hepatitis C Virus Genotype from Punjab, India - Expanding Classification of Hepatitis C Virus into 8 Genotypes.
    J Infect Dis. 2018 Jun 30. pii: 5047409. doi: 10.1093.
    PubMed     Abstract available


  66. HELFRITZ FA, Bojkova D, Wanders V, Kuklinski N, et al
    Methylene Blue Treatment of Grafts during Cold Ischemia time Reduces the Risk of HCV Transmission.
    J Infect Dis. 2018 Jun 23. pii: 5043304. doi: 10.1093.
    PubMed     Abstract available


  67. LIDOFSKY A, Holmes JA, Feeney ER, Kruger AJ, et al
    Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection.
    J Infect Dis. 2018 Jun 4. pii: 5032604. doi: 10.1093.
    PubMed     Abstract available


    March 2018
  68. RAGONNET-CRONIN M, Jackson C, Bradley-Stewart A, Aitken C, et al
    Recent and Rapid Transmission of HIV among People who Inject Drugs in Scotland Revealed through Phylogenetic Analysis.
    J Infect Dis. 2018 Mar 13. pii: 4931169. doi: 10.1093.
    PubMed     Abstract available


  69. COOPER CL
    Now is the Time to Quickly Eliminate Barriers along the Hepatitis C Cascade of Care.
    J Infect Dis. 2018 Mar 9. pii: 4925219. doi: 10.1093.
    PubMed    


  70. LAMOURY FMJ, Bajis S, Hajarizadeh B, Marshall AD, et al
    Evaluation of the Xpert(R) HCV Viral Load Fingerstick point-of-care assay.
    J Infect Dis. 2018 Mar 9. pii: 4925218. doi: 10.1093.
    PubMed     Abstract available


  71. STROUVELLE VP, Braun DL, Vongrad V, Scherrer AU, et al
    No Effect of Pegylated Interferon-alpha on Total Hiv-1 DNA Load in HIV-1/HCV Coinfected Patients.
    J Infect Dis. 2018 Mar 8. pii: 4924783. doi: 10.1093.
    PubMed     Abstract available


    January 2018

  72. Erratum: Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2018 Jan 27. pii: 4827080. doi: 10.1093.
    PubMed    


  73. ROLT A, Le D, Hu Z, Wang AQ, et al
    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093.
    PubMed     Abstract available


  74. SANAKA S, Kasarala GR, Tillmann HL
    A Downside to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression.
    J Infect Dis. 2018 Jan 21. pii: 4770294. doi: 10.1093.
    PubMed     Abstract available


  75. REID M, Ma Y, Scherzer R, Price JC, et al
    Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
    J Infect Dis. 2018 Jan 3. pii: 4786614. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  76. PERUMALSWAMI PV, Talal AH
    Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders.
    J Infect Dis. 2017 Dec 26. pii: 4774700. doi: 10.1093.
    PubMed    


  77. STEPANOVA M, Thompson A, Doyle J, Younossi I, et al
    Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
    J Infect Dis. 2017 Dec 26. pii: 4774699. doi: 10.1093.
    PubMed     Abstract available


    November 2017
  78. ROSENBERG BR, Freije CA, Imanaka N, Chen ST, et al
    Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Abstract available


  79. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    PubMed     Abstract available


  80. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Abstract available


    September 2017
  81. TALAL AH, Dumas EO, Bauer B, Rejman RM, et al
    Hepatic Pharmacokinetics and Pharmacodynamics with Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
    J Infect Dis. 2017 Sep 27. pii: 4210613. doi: 10.1093.
    PubMed     Abstract available


    August 2017
  82. HEIMER R, Binka M, Koester S, Grund JC, et al
    Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Abstract available


  83. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Abstract available


    April 2017
  84. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Abstract available


    March 2017
  85. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Abstract available


    October 2016
  86. HALLAGER S, Brehm Christensen P, Ladelund S, Rye Clausen M, et al
    Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population - a Danish cohort study.
    J Infect Dis. 2016.
    PubMed     Abstract available


    September 2016
  87. HENGST J, Falk CS, Schlaphoff V, Deterding K, et al
    DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.
    J Infect Dis. 2016.
    PubMed     Abstract available


  88. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Abstract available


    July 2016
  89. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: